For the next three weeks, I will publish a series focusing on the corporate sale process. This series is written for commercial-stage pharma or biotech company facing a sale process in the next 12–24 months.
The three issues form a connected narrative arc — 18-month preparation, then strategic alternatives review mechanics, then balance-sheet cleanup.
I will publish a new article each Monday starting today and for the next three weeks, and for those interested I can provide access to form working documents behind the subscriber wall thereafter.
• Issue 1: The 18 Months Before the Banker, will discuss “strategic alternatives,” “pre-sale,” “diligence room,” “litigation cleanup,” “ATM offering,” “carve-out.”
• Issue 2: The Strategic Alternatives Review, will discuss “strategic alternatives review,” “transaction committee,” “banker mandate,” “fiduciary out,” “no-shop,” “Revlon duties.”
• Issue 3: What Your Buyer’s Diligence Team Sees Before You Do, will discuss “balance sheet cleanup,” “assignment audit,” “change of control,” “IP chain of title,” “280G,” “regulatory readiness.”
The first installment will drop later today, May 26. As always, I am available to discuss or chat about these or other topics.
Stay tuned, I hope you find this useful.
J


